Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | FURIN | P09958 | 9/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.36 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.35 |
| ▸ | CHRNG | P07510 | 1/20 | 0.35 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.35 |
| ▸ | CHRND | Q07001 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 2/20 | 0.35 |
| ▸ | HPN | P05981 | 2/20 | 0.35 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | Q9HBH1 | 1/20 | 0.35 | |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21179855 | 0.93 | C3AR1 (0.41) | HTTFURINSMN1; SMN2ROCK2KLKB1 | |
| SCHEMBL22138596 | 0.92 | FURIN (0.39) | HTTFURINSMN1; SMN2ROCK2KLKB1 | |
| SCHEMBL20705515 | 0.92 | FURIN (0.39) | HTTFURINSMN1; SMN2ROCK2KLKB1 | |
| SCHEMBL22138594 | 0.92 | FURIN (0.39) | HTTFURINSMN1; SMN2ROCK2KLKB1 | |
| SCHEMBL27447192 | 0.92 | FURIN (0.39) | HTTFURINSMN1; SMN2ROCK2KLKB1 | |
| SCHEMBL24296990 | 0.91 | FURIN (0.40) | HTTFURINSMN1; SMN2ROCK2KLKB1 | |
| SCHEMBL15699830 | 0.89 | SIRT5 (0.39) | HTTFURINCHRNA1CHRNGCHRNB1 | |
| SCHEMBL19687790 | 0.88 | SIRT5 (0.39) | HTTFURINCHRNA1CHRNGCHRNB1 | |
| SCHEMBL24296989 | 0.87 | FURIN (0.43) | FURINROCK2CHRNA1CHRNGCHRNB1 | |
| SCHEMBL23051312 | 0.87 | MAP1LC3B (0.38) | HTTFURINCHRNA1CHRNGCHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210162058-A1 | ENGINEERED POLYPEPTIDE CONJUGATES USING TRANSGLUTAMINASE | RINAT NEUROSCIENCE CORP. (US) | 2021-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210162058-A1 | ENGINEERED POLYPEPTIDE CONJUGATES USING TRANSGLUTAMINASE | TGM2, TGM3, TGM1 | HTT 853/4885FURIN 842/4885SMN1; SMN2 4193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.